Navigation Links
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
Date:2/16/2011

SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the first patient received subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze(™ technology (rHuPH20, recombinant human hyaluronidase). This represents the second Roche cancer medicine, in addition to Herceptin® SC (trastuzumab), to enter a Phase 3 registration study as part of the Halozyme-Roche collaboration. Initiation of the clinical trial has triggered a milestone payment of $5 million to Halozyme. MabThera is approved to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) using different induction and maintenance treatments that are currently given intravenously (IV).

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"The start of this Phase 3 subcutaneous MabThera trial in patients with follicular NHL signifies another major achievement for the Halozyme-Roche partnership, and represents the second Roche target to begin a pivotal trial. I congratulate the team on this important accomplishment," said Gregory Frost, Ph.D., Halozyme's president and CEO. "MabThera is the standard of ca
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
2. Halozyme Receives $5.5 Million Payment From Baxter
3. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
4. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
5. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics to Host Research Day for Investors and Analysts
8. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
9. Halozyme Therapeutics to Present at Upcoming Investor Conferences
10. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
11. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... not your parents' generation of corporate leaders. , ,A ... cross the lips of gray-haired, gray-suited corporate executives. Today, ... Wisconsin doesn't yet have it. , ,At the Olympia ... academic and arts groups met to brainstorm strategies for ...
... Wis. - The 53 Wisconsin companies that won ... Innovation Research (SBIR) and Small Business Technology Transfer (STTR) ... at an upcoming banquet in Madison. , ,The awards ... transfer workshop. The workshop will focus on SBIR/STTR funding ...
... 30 years ago, then-Gov. Pat Lucey and the Wisconsin ... property taxes. It was a bipartisan decision that has ... times and foreign competition threatened. , ,Today, Wisconsin policymakers ... a competitive toehold by reducing state taxes that discourage ...
Cached Biology Technology:Tech leaders call for more creativity 2Modernizing the tax code can make Wisconsin tech businesses more competitive 2Modernizing the tax code can make Wisconsin tech businesses more competitive 3
(Date:4/24/2014)... turtle in North America, weighing in at up to ... from Florida and the University of Vermont have discovered ... , Examining museum specimens and wild turtles, the scientists ... Once heavily hunted for turtle meat alligator snapper ... the 1960s the riverine populations have been deeply ...
(Date:4/23/2014)... and other chronic inflammatory disorders among people of lower ... reduced exposure to the microbes that thrive in rural ... article, published in the journal Clinical & Experimental ... who have less access to green spaces may be ... by immune system dysfunction. , When our immune systems ...
(Date:4/23/2014)... in their mid-thirties and forties, face a devastating ... two decades. "Mutant" protein clusters, long blamed for ... the primary focus of therapies in development by ... Prof. Gerardo Lederkremer and Dr. Julia Leitman of ... Immunology, in collaboration with Prof. Ulrich Hartl of ...
Breaking Biology News(10 mins):Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3
... some have argued, can be reversed with a large-scale ... liquefied sulfur dioxide in the stratosphere or building tens ... to filter out carbon dioxide. ... of Atmospheric and Oceanic Sciences and a member and ...
... biological tit for tat may hold clues to improving ... type 1 diabetes, according to a Medical College of ... attacks insulin-producing cells causing high blood glucose levels that ... an immunologist in the MCG Center for Biotechnology and ...
... Ind. - Purdue University researchers found a mechanism that ... how to keep that switch turned on may be ... Nicholas Carpita, a professor of botany and plant pathology, ... in plant development by shutting off genes involved in ...
Cached Biology News:No quick or easy technological fix for climate change, researchers say 2No quick or easy technological fix for climate change, researchers say 3No quick or easy technological fix for climate change, researchers say 4High blood sugar's impact on immune system holds clues to improving islet cell transplants 2High blood sugar's impact on immune system holds clues to improving islet cell transplants 3Researchers find nature's shut-off switch for cellulose production 2
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Recombinant Viral CCI/Fc Chimera, CF...
... • Guinea Pig serum is collected from fasted ... N-02: Citrate N-04: Heparin (Na) ... Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: ...
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
Biology Products: